Table 1

Baseline characteristics of the entire cohort and the subgroup of patients with CAD: categorical variables

VariableEntire cohortPatients with CAD
GlimepirideGlipizideGlyburideGlimepirideGlipizideGlyburide
n2,5374,3254,279341584580
Male1,370 (54.0)2,422 (56.0)2,408 (56.3)233 (68.3)400 (68.5)419 (72.2)
Caucasian2,044 (80.6)3,237 (74.8)3,207 (74.9)285 (83.6)488 (83.6)477 (82.2)
Missing86 (3.4)129 (3.0)131 (3.1)10 (2.9)10 (2.5)11 (2.5)
Current smoker254 (10.0)459 (10.6)425 (9.9)34 (10.0)49 (8.4)50 (8.6)
Never836 (33.0)1,329 (30.7)1,326 (31.0)97 (28.4)145 (24.8)147 (25.3)
Passive4 (0.2)10 (0.2)9 (0.2)0 (0.0)2 (0.3)0 (0.0)
Quit739 (29.1)1,241 (28.7)1,209 (28.3)157 (46.0)272 (46.6)240 (41.4)
Missing704 (27.7)1,286 (29.7)1,310 (30.6)53 (15.5)116 (19.9)143 (24.7)
ACE/angiotensin receptor blocker inhibitors1,344 (53.0)2,213 (51.2)2,220 (51.9)245 (71.8)378 (64.7)382 (65.9)
Cholesterol-lowering medication1,158 (45.6)1,922 (44.4)1,787 (41.8)264 (77.4)422 (72.3)401 (69.1)
Plavix221 (8.7)333 (7.7)322 (7.5)90 (26.4)101 (17.3)113 (19.5)
Aspirin669 (26.4)1,029 (23.8)1,017 (23.8)178 (52.2)277 (47.4)263 (45.3)
CAD341 (13.4)584 (13.5)580 (13.6)341 (100)584 (100)580 (100)
Heart failure197 (7.8)319 (7.4)326 (7.6)82 (24.0)141 (24.1)150 (25.9)
New diabetes249 (9.8)411 (9.5)280 (6.5)47 (13.8)71 (12.2)43 (7.4)
  • Data are n (%).